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We aimed to identify the role of vascular endothelial growth factor (VEGF) and mono-
cyte chemoattractant protein (MCP-1) as a serum biomarker of symptomatic carotid
atherosclerotic plaque in North Indian population. Individuals with symptomatic carotid
atherosclerotic plaque have high risk of ischemic stroke. Previous studies from western
countries have shown an association between VEGF and MCP-1 levels and the incidence
of ischemic stroke. In this study, venous blood from 110 human subjects was collected, 57
blood samples of which were obtained from patients with carotid plaques, 38 neurological
controls without carotid plaques, and another 15 healthy controls who had no history of
serious illness. Serum VEGF and MCP-1 levels were measured using commercially avail-
able enzyme-linked immunosorbent assay.We also correlated the data clinically and carried
out risk factor analysis based on the detailed questionnaire obtained from each patient. For
risk factor analysis, a total of 70 symptomatic carotid plaque cases and equal number of
age and sex matched healthy controls were analyzed. We found that serum VEGF levels in
carotid plaque patients did not show any significant change when compared to either of the
controls. Similarly, there was no significant upregulation of MCP-1 in the serum of these
patients.The risk factor analysis revealed that hypertension, diabetes, and physical inactiv-
ity were the main correlates of carotid atherosclerosis (p<0.05). Prevalence of patients
was higher residing in urban areas as compared to rural region. We also found that patients
coming from mountain region were relatively less vulnerable to cerebral atherosclerosis
as compared to the ones residing at non mountain region. On the contrary, smoking, obe-
sity, dyslipidemia, alcohol consumption, and tobacco chewing were not observed as the
determinants of carotid atherosclerosis risk in North India (p> 0.05). We conclude that
the pathogenesis of carotid plaques may progress independent of these inflammatory
molecules. In parallel, risk factor analysis indicates hypertension, diabetes, and sedentary
lifestyle as the most significant risk factors of ischemic stroke identified in North India.This
could be helpful in early identification of subjects at risk for stroke and devising health care
strategies.
Keywords: carotid atherosclerotic plaque, vascular endothelial growth factor, serum protein levels, monocyte
chemoattractant protein, enzyme-linked immunosorbent assay
INTRODUCTION
Stroke continues to be the principal contributor of functional
impairment and disability in adults and is the second lead-
ing cause of death worldwide (Feigin, 2005). It is character-
ized by a sudden reduction of blood flow in an area of the
brain resulting in neurological deficits. Ischemia can produce a
transient ischemic attack (TIA) (Kiely et al., 1993) which was
defined as acute onset of focal neurological deficit lasting less
than 24 h. Deposition of atherosclerotic lesions/plaque in carotid
arteries may produce a high risk of ischemic stroke (Aydiner
et al., 2007). Therefore, the identification of molecular biomark-
ers in serum of patients presenting with carotid plaque would
assist in the early detection of patients at risk for the ischemic
stroke.
Vascular endothelial growth factor (VEGF) has been strongly
implicated in brain ischemia (Cobbs et al., 1998). It plays a variety
of roles in the disease process, such as forming new and porous
blood vessels through a process known as angiogenesis, which
stimulates endothelial cells to proliferate and migrate to areas
of the brain affected by ischemia (Ferrara et al., 1991; Dvorak
et al., 1995; Nagy et al., 2002; Hoeben et al., 2004). In addi-
tion to its known role as an angiogenic growth factor, VEGF
confers neuroprotection by reducing the neurological damage
that occurs after ischemic insult (Yang et al., 2012). VEGF and
its receptor VEGFR1/soluble form of full-length transmembrane
receptor (sflt-1) are expressed at significantly higher levels in rat
neurons after occlusion of the middle cerebral artery (Lennmyr
et al., 1998). Analysis of human post-mortem brain tissue after an
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ischemic stroke has shown that different isoforms of VEGF, includ-
ing VEGF165 and VEGF189, as well as their soluble receptors, are
expressed at higher levels than in samples from patients without
ischemic stroke (Krupinski et al., 1999). Because VEGF plays a
crucial role in physiological and pathophysiological angiogenesis,
measurement of VEGF in serum is of diagnostic and prognostic
value as a marker for atherothrombotic disease. Moreover, inflam-
matory cytokines that are induced by VEGF, such as monocyte
chemoattractant protein (MCP-1) have been previously shown
to be involved in the pathogenesis and progression of carotid
atherosclerosis (Yamada et al., 2003). Therefore, to further elu-
cidate the role of VEGF and MCP-1 as potential biomarkers in
ischemic stroke, we sought to estimate their levels in the sera of
stroke patients presenting with carotid atherosclerotic plaques in
the North Indian population.
MATERIALS AND METHODS
The study was initiated after getting approval from the ethics com-
mittee of the Institute. The study was conducted in the Doppler
laboratory, Department of Neurology, Post Graduate Institute of
Medical Education and Research (PGIMER), Chandigarh, India.
Following were the Inclusion criteria for enrollment:
1. Patients of ischemic stroke/TIA> 15 years of age
2. Stroke in the anterior circulation confirmed by neuroimaging-
Cranial CT or MRI scan
3. Presence of extracranial atherosclerotic disease on cervical
duplex ultrasound
4. Fully informed consent available
The Exclusion criteria were:
1. Patients of hemorrhagic stroke or venous strokes
2. Patients with cardioembolic strokes or family history of
thrombotic predisposition
3. Patients with short neck, bony abnormality precluding a
cervical duplex study
4. Patients with a high cervical bifurcation on duplex ultrasound
5. Pregnancy
SUBJECTS FOR VEGF AND MCP-1 ESTIMATION
We defined symptomatic carotid atherosclerotic plaque as aggrega-
tion of plasma lipids (especially cholesterol), cells (smooth muscle
cells and monocytes/macrophages), and connective tissue matrix
(proteoglycans) in carotid artery as detected by duplex ultra-
sound (Garcia and Khang-Loon, 1996). Symptomatic patients
with age above 15 years; TIA; left or right hemiparesis underwent
duplex ultrasound with carotid atherosclerotic plaque. Detected
in anterior circulation were included in the study.
Patients who had symptoms of TIA but were not positive for
carotid plaque as reported by Doppler ultrasound constituted the
neurological controls. All volunteer asymptomatic family mem-
bers and individuals who accompanied the patients with no history
of serious illness constituted the healthy control group. Healthy
controls were not subjected to Doppler examination. However,
after informed consent, their blood samples were collected and
further processed in the neuroscience research lab. The blood sam-
ples of all the patients as well as controls were collected randomly
without considering any time limit. It should be noted that the
patients who came for follow up a few months after they encoun-
tered stroke were also included in the study. Table 1 shows the study
population for protein estimation and the duration of disease for
patients and neurological controls.
The severity of carotid atherosclerosis was graded according
to the stenosis percentage. (1) Mild: with intima media thickness
(IMT) >0.08 cm in CCA (common carotid artery) (2) Moderate:
stenosis<50% in ICA (internal carotid artery) (3) Severe: stenosis
>50% in ICA (internal carotid artery).
VEGF and MCP-1 estimation
Vascular endothelial growth factor and MCP-1 protein levels
secreted in the serum of ischemic stroke patients and controls
were quantified by enzyme-linked immune assay (Quantikine kits
obtained from R&D Systems). All samples were analyzed in dupli-
cate and subsequently used in all further statistical analysis. The
assay sensitivity was 5.0 pg/ml for VEGF and 9.0 pg/ml for MCP-1.
Total protein and bovine serum albumin estimation
Total protein and albumin were estimated using Biorad protein
assay kit. Five dilutions of a protein standard (representing pro-
tein solution to be tested) were prepared. Protein solutions were
assayed in duplicate at linear range of 8.0 mg/ml to 80 mg/ml
approximately. Standard and sample solution of 160 ml each were
dispensed into different microtiter plate wells followed by addi-
tion of 40 ml of dye reagent concentrate. Multi channel pipet (to
dispense the reagent) was used to mix sample and reagent thor-
oughly followed by incubation for 5 min at room temperature.
Then absorbance was measured using microplate enzyme-linked
immunosorbent assay (ELISA) reader at 595 nm and samples
were analyzed for total protein. Levels of VEGF and MCP-1 were
normalized to total protein and further subjected to statistical
analysis.
RISK FACTOR ANALYSIS
The patients with carotid atherosclerotic disease and equal num-
ber of age and sex matched healthy controls were analyzed. All
the IS patients were interviewed after the duplex ultrasound and
the clinical and socio-demographic details including hyperten-
sion, diabetes, and lipid profile were tabulated in a pre-validated
questionnaire. Socio-demographic details such as body mass index
Table 1 | Study Population for VEGF and MCP-1 estimation.
Sample
size (n)
Number of symptomatic patients and
controls related to duration of disease
1–3
weeks
1–6
months
7–12
months
More than 12
months
Stroke (with
carotid plaque)
57 7 30 5 8
Neurological
controls (without
carotid plaque)
38 6 19 4 9
Healthy controls 15
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(BMI), alcohol consumption, tobacco chewing, smoking, physical
inactivity, geographic location (rural/urban), topographic region
(mountaineer/plain) was also included. Similar details were col-
lected from controls. Proper informed consent was taken from all
the participants. Those who were unable to give their consent were
recruited on the basis of an accompanying person’s signed agree-
ment. Illiterate people who were not capable to read the agreement
were explained the content of the form verbally and were asked to
place their thumbprints on the form.
MEASURES
Age and gender of the patients and controls was recorded in the
clinical pro forma. Most of the variables are self explanatory or
otherwise stated.
CLINICAL PARAMETERS
Hypertension
Patients were categorized as hypertensive if the blood pressure
was more than 140/90 mmHg or there was a history of receiving
anti-hypertensive medications.
Diabetes mellitus
Patients were interviewed whether they were diabetic or non-
diabetic. They were confirmed diabetic if their fasting plasma
glucose was more than 126 mg/dl as per their reports or if they
were receiving any anti-diabetic medications.
Lipid profile
Levels of total cholesterol, high-density lipoprotein (HDL), low-
density lipoprotein (LDL), and triglycerides were noted from
patients. Patients who did not have lipid test reports were asked to
undergo the test and report the levels.
SOCIO-DEMOGRAPHIC PARAMETERS
Body mass index
Patients whose BMI was in the range 25–29.9 were considered
overweight and whose BMI fell between 30 and 34.9 were obese.
Smoking
Smoking was classified into two categories: current smokers and
non-smokers. Current smokers represented as reported when
interviewed. Former smokers included those who smoked for a
period of 10 years before stroke onset. Non-smokers were defined
as those who had never smoked in their lifetime and the ones who
had quit for more than 10 years before the onset of disease.
Physical inactivity
On the basis of low (only walking), moderate, or vigorous exer-
cise, patients were classified as physically active and non-active.
Low (only walking) activity was under physically inactive cate-
gory while moderate and vigorous activity was grouped under
physically active category.
Alcohol consumption
Patients were categorized into alcohol consumers and non-alcohol
consumers on the basis of alcohol intake. Amount of alcohol was
also recorded in the questionnaire from alcohol consumers.
STATISTICAL ANALYSIS
For VEGF and MCP-1 estimation, Mann–Whitney U test was used
and p< 0.05 was considered statistically significant. Chi-square
test (Pearson Uncorrected) was used as a test of significance for
socio-demograhic analysis and p-value less than 0.05 was consid-
ered as significant. Whenever the values in any of the cells of the
contingency table were below 10 Fisher’s exact test was applied.
RESULTS
The study population comprised of 110 subjects of whom 57
symptomatic patients with carotid plaque, 38 symptomatic neu-
rological controls without carotid plaque, and asymptomatic 15
healthy controls were enrolled for VEGF and MCP-1 estimation.
Baseline characteristics of the study population for risk factor
analysis are described in Table 2. Prevalence of IS in North India
was found more in men than women (71.4% in men). The disease
is more commonly seen in elderly people (51.4%). Our results
revealed that there was no significant upregulation of VEGF in
carotid plaque cases as compared to controls. We also studied
MCP-1 levels but here also we did not observe any significant
upregulation.
SERUM VEGF LEVELS IN CAROTID PLAQUE PATIENTS
The mean of the VEGF concentration in serum of carotid plaque
patients versus healthy controls was 9.7± 0.798 pg/ml while the
mean VEGF concentration in serum of carotid plaque patients
versus neurological controls was 16.468± 1.48 pg/ml. VEGF levels
were not found to be significantly elevated in patients as compared
to either of the controls (p> 0.05) (Figure 1).
SERUMMCP-1 LEVELS IN CAROTID PLAQUE PATIENTS
The mean of the MCP-1 concentration in serum of carotid plaque
patients versus healthy controls was 4.913± 0.22 pg/ml while the
mean MCP-1 concentration in serum of carotid plaque patients
versus neurological controls was 3.904 pg/ml. We did not observe
any significant alteration in MCP-1 levels when compared to either
of the controls (p> 0.05) (Figure 2).
GEOGRAPHICAL DISTRIBUTION, DEMOGRAPHY, AND RISK FACTOR
ANALYSIS
Clinical details and socio-demographic characteristics of carotid
plaque patients in North India are described in Table 3. The risk
factor analysis revealed that hypertension, diabetes, and physical
inactivity were the main correlates of carotid atherosclerosis
Table 2 | Baseline characteristics of study population for
clinical/socio-demographic analysis.
Number of carotid plaque patients 70
Men 50 (71.4%)
Mean age (years) 59.3±12.2 years
Range (years)
30–39 2.9%
40–49 17.6%
50–59 27.9%
60 and above 51.4%
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FIGURE 1 | Levels of VEGF in serum of stroke patients, healthy controls, and neurological controls. Group means were plotted ±SE. No significant
difference was observed among the given conditions (p>0.05). Data was analyzed by Mann–Whitney Test. Levels of VEGF were normalized to total serum
protein. (S, Stroke Patients; NC, Neurological Controls; HC, Healthy Controls).
FIGURE 2 | Levels of MCP-1 in serum of stroke patients, neurological control, and healthy control subjects. Group means were plotted ±SE. No
significant difference was observed among the given conditions (p>0.05). Data was analyzed by Mann–Whitney Test. Levels of VEGF were normalized to total
serum protein. (S, Stroke Patients; NC, Neurological Controls; HC, Healthy Controls).
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Table 3 | Clinical details and socio-demographic characteristics of
ischemic stroke patients in North India.
Clinical details Prevalence
(%)
Socio-demographic
characteristics
Prevalence
(%)
Hypertension 72.7 Smoking 20.5
Diabetes 28.7 Alcohol consumption 29.4
Total cholesterol Physical inactivity 82.08
250–390 mg/dl (high) 5 Tobacco
consumption
6
<250 97 Obesity 6
HDL cholesterol Fish consumption 33.8
<40 mg/dl (high risk) 38.8 Non-vegetarian 56
>40 mg/dl 61.1 BMI; overweight
subjects
28
Triglycerides Topography (plain
region)
88.05
>225 mg/dl (high risk) 8.5 Geographic location
(urban)
70
<225 mg/dl 88.5
LDL cholesterol
>160 mg/dl (high risk) 4.8
<160 mg/dl (protective) 95
LDL, low-density lipoprotein; HDL, high-density lipoprotein; BMI, body mass
index.
(p< 0.05). Prevalence of patients was higher residing in urban
areas as compared to rural region. We also found that patients
coming from mountaineer region were relatively less vulnerable
to cerebral atherosclerosis as compared to the ones residing in
non-mountainous region. On the contrary, smoking, obesity, dys-
lipidemia, alcohol consumption, and tobacco chewing were not
observed as the determinants of carotid atherosclerosis risk in
North India (p> 0.05). Table 4 illustrates the odd ratios, relative
risk at 95% confidence interval and the p-values of clinical and
socio-demographic parameters.
DISCUSSION
Ischemic stroke has become a major health problem worldwide
(Murray and Lopez, 1997), and therefore it is crucial to identify
novel biomarkers and preventive strategies for the treatment of
the disease. Brain ischemia accounts for a significant proportion
of all strokes, and atherosclerosis is considered to be the major
cause of most of the brain infarcts (Fuster et al., 1992; Ross,
1999). The atheromatous plaques represent a series of specific
cellular and molecular responses that include lipoprotein, hemato-
logic, and inflammatory components (Ross, 1999). Various reports
have shown that inflammation may promote atherosclerosis and
plaque formation by elevating serum levels of fibrinogen (Ernst
and Koenig, 1997), leukocytes (Ernst et al., 1987), clotting factors
(Juhan Vague et al., 1996), and cytokines (Dinerman et al., 1990)
and by altering the metabolism of endothelial cells and mono-
cyte/macrophages (Dinerman et al., 1990; Celletti et al., 2001).
Viral and bacterial infections reflected in elevated levels of vari-
ous acute-phase proteins (Mattila, 1989) may be partly responsible
for the inflammatory processes which in turn may be associated
Table 4 | Risk factors of IS with odd ratios, relative risks at 95% CI and
p-values; p-values<0.05 significant.
Variables Odds ratio
(OR) 95%
confidence
interval
Relative risks
(RR) 95%
confidence
interval
p-value
*Hypertension 12.06 (4.7–31.5) 3.06 ( 2.04–4.46) <0.001
*Diabetes# 4.68 (1.50–15.5) 1.73 (1.19–2.13) 0.003
Alcohol consumption 1.26 (0.57–2.79) 1.11 (0.76–1.56) 0.519
Smoking 1.92 (0.72–5.19) 1.32 (0.85–1.78) 0.148
Obesity# 0.92 (0.19–4.18) 0.95 (0.32–1.73) 1.000
Geographic location 1.53 (0.70–3.34) 1.23 (0.84–1.89) 0.243
BMI (25–29.9 kg/m2) 1.05 (0.46–2.38) 1.03 (0.64–1.52) 0.886
Tobacco consumption# 1.83 (0.27–15.0) 1.27 (0.45–1.85) 0.683
*Physical inactivity 4.73 (2.0–11.1) 1.95 (1.3–2.6) <0.001
*Statistically significant variable.
#Fisher’s exact test.
with the occurrence of ischemic symptoms (Mattila et al., 1998).
A study identified a particular protein in the sera of healthy sub-
jects, which was initially absent in acute ischemic stroke patients
and reappeared after treatment (Kashyap et al., 2006). This finding
suggests that the protein may be useful as an important diagnostic
marker. Moreover, several growth factors, such as basic fibroblast
growth factor (bFGF), VEGF, and MCP-1 are known to play an
essential role in mediating recovery in ischemic stroke patients.
The main objective of the current study was to improve our
knowledge about the potential biomarkers in the sera of patients
presenting with carotid plaque. Since carotid atherosclerotic
lesions may develop ischemic stroke, a better understanding and
identification of these biomarkers may lead to improved patient
care and novel therapeutic approaches for treatment of ischemic
stroke. Our study revealed no alteration in the levels of VEGF and
MCP-1 after ELISA was conducted. We used various parameters
such as socio-demographic variables based on certain risk factors
for carotid plaque development such as advanced age, sex, hyper-
tension, diabetes mellitus, and physical inactivity. The male/female
sex ratio for stroke in India has been estimated to be 1.7:1 (Sethi,
2002). We noticed that elderly people above 60 years of age are
the most affected individuals (51.4%) with men more likely to
develop the disease compared to women (71.4% men). In relation
to this we report a significant association of hypertension with
increased risk of stroke [R 12.06 at 95% CI (4.7–31.5); p< 0.05].
Similarly, diabetes mellitus is identified as a putative risk factor
for stroke in case-control studies. Our data showed that diabetic
individuals are more vulnerable to the disease compared with
the ones whose blood sugar level is normal. A significant asso-
ciation of diabetes with the risk of ischemic stroke identifies it
to be an important risk factor in North Indian population, like
previous studies [OR 4.68 at 95% CI (1.50–15.5); p< 0.05]. It
is interesting to report there is a conflicting finding published as
Dubbo study which did not report diabetes as a risk factor for
stroke (Simons et al., 1998). Several lines of evidence suggest a
link between physical inactivity and ischemic heart disease (Batty,
2002). Our data is consistent with the previous reports suggesting
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physical inactivity to be significantly associated with stroke risk
(Paffenbarger and Wing, 1967; Wannamethee and Shaper, 1992;
Hu et al., 2000) [OR 4.73 at 95% CI (2.0–11.1); p< 0.05]. This
finding is consistent with the previous reports (Lanska, 1993).
On the other hand no significant association of obesity, smoking,
dyslipidemia, alcohol, and tobacco consumption with the stroke
risk was found. The result is consistent with the Dubbo study
that revealed alcohol intake and smoking as a non-determinant
of stroke and indirectly supports of previous studies in which
high alcohol consumption has been associated to stroke risk in
comparison to moderate consumption. (Gill et al., 1991; Jamrozik
et al., 1994; Caicoya et al., 1999; Malarcher et al., 2001). We also
did not find any significant linkage of dyslipidemia with the risk
of stroke in this report. This may be due to the fact that most
of the stroke patients were being followed up and were put on
medications. The current finding reveals that the prevalence of
stroke was greater among stroke patients residing in urban places
(Brown et al., 1996; Sacco et al., 1998; Fang, 2012) than the ones
from rural areas but the difference was not statistically significant.
The causes to this observation have previously been pointed out to
result from less active lifestyle of urban residents than their rural
counterparts (Banerjee and Das, 2006; Joshi et al., 2006). There-
fore, urbanization might play a crucial role in the pathogenesis of
the disease.
This finding is not in agreement with those of many previous
reports from outside India where serum VEGF level was found
to be upregulated in patients of ischemic stroke. The probable
reason for unaltered expression of VEGF in systemic blood flow
is enigmatic. We ascribe this unusual finding to limited release of
this growth factor localized in and around the damaged tissue than
being secreted in circulating blood stream or partly a result of acti-
vated negative feedback system (with a speculation that increased
VEGF expression in ischemic penumbra may produce a molecular
mediator that may turn on an inhibitory feedback mechanism).
Expectedly, MCP-1 being induced by the upregulation of VEGF,
its level was also found to be equally unaltered (Marumo et al.,
1999). Since Cooper et al. (1999) observed an elevated expression
of VEGF in experimental diabetes many studies have estimated
the VEGF levels in different diseases (Slevin et al., 2000; Andrew
et al., 2002; Blann et al., 2002). Also an enhanced expression of
MCP-1 in patients with ischemic stroke and myocardial infarction
have been observed in some studies (Arakelyan et al., 2005). It has
been suggested that lifestyle of an individual has great impact on
risk factors associated with stroke (Welin et al., 1987). Individuals
with hypertension and diabetes have twice to sixfold chances of
having stroke as per published reports (Kannel and McGee, 1979;
Wolf et al., 1992; Burchfiel et al., 1994). Similarly, the results of
Framingham Heart Study revealed the effect of diabetes on cere-
bral and peripheral arteries (Benjamin et al., 1998). Individual
studies in India have estimated the prevalence rate of the ischemic
stroke from 21/100,000 for individuals in 20–40 years of age group
to 625/100,000 above 60 years age and 27–34/100,000 in the 35–44
age group to 822–1116/100,000 above 75 years age (Bansal et al.,
1973; Razdan et al., 1989; Dhamija et al., 2000; Dalal, 2008; Srid-
haran, 2009). Moderate physical exercise is reported to reduce
the depression rate and prevents the occurrence of heart disease
and stroke by lowering the blood pressure and raising the level
of HDL cholesterol in blood (Shephard, 1997; Thompson et al.,
2003) which are in support to a study done in Italian popula-
tion which stated that moderate amount of exercise may help
in reducing the risk of stroke (Menotti and Seccareccia, 1985).
The current data shows that people residing at mountain region
have low rates of stroke as compared to the ones residing at
plain region. Another modifiable factor, cigarette smoking, has
been reported to be associated with all types of stroke includ-
ing ischemic stroke, intra-cerebral, and subarachnoid hemorrhage
(Shinton and Beevers, 1989; Juvela et al., 1993; Kurth et al., 2003).
In addition, risk of having stroke declines when smoking is discon-
tinued (Feigenbaum, 1993). In view of these contradictory reports,
alcohol consumption, dyslipidemia, and smoking as a stroke pre-
dictor remain controversial pending population-based prospective
studies.
The present study had some limitations like risk factors in
other subtypes of stroke, socio-demographic parameters such as
depression or stress were not assessed as well as no mechanistic
information regarding stroke prevention and rehabilitation was
provided. Still there is a great promise in the search for serum
biomarkers to help in the prognosis of atherosclerotic disease but
many theoretical and practical challenges stand in the way. Fur-
ther performing studies with a large patient cohort focusing on
risk factors of stroke are however, necessary to examine additional
biomarkers including VEGF and MCP-1 with reduced sample time
after stroke onset to corroborate this preliminary data.
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